Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
Scope
The report provides information on the key drivers and challenges of the hepatitis B therapeutics market. Its scope includes -
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
Keywords
Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
Scope
The report provides information on the key drivers and challenges of the hepatitis B therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan hepatitis B therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HBsAg release blocker, HBV DNA polymerase inhibitor, HBV DNA polymerase inhibitor and immunomodulator, HBV DNA polymerase inhibitor and microtubule assembly inhibitor, HBV therapeutic vaccine, HBV therapeutic vaccine and HBV DNA polymerase inhibitor, Hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, Immunomodulator, Protease inhibitor and others.
- Analysis of the current and future competition in the seven key countries hepatitis B therapeutics market. Key market players covered are GlaxoSmithKline, Bristol-Myers Squibb, Daewoong Pharmaceutical Co., Ltd., Chongqing Jiachen Biotechnology Ltd, Chongqing Tongjunge Co., Ltd., LG Life Sciences, Ltd, Bristol-Myers Squibb Company, Phytrix Inc., Medivir AB, AiCuris GmbH & Co. KG, Gilead Sciences, Inc., VectorLogics, Inc., Genexine Co., Ltd., GenPhar, Inc., Cytheris SA, Bolder Biotechnology, Inc, ImQuest Life Sciences, Aduro BioTech, Agenix Limited, Xenetic Biosciences plc, MOLOGEN AG, NanoBio Corporation, Inbiopro Solutions Pvt. Ltd., Gilead Sciences, Merck & Co. Inc. and Novartis AG,
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hepatitis B therapeutics market.
- Analysis of key recent licensing and partnership agreements in hepatitis B therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis B therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis B therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global hepatitis B therapeutics market landscape? – Identify, understand and capitalize.
Keywords
Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 HEPATITIS B THERAPEUTICS - INTRODUCTION
2.1 Overview
2.2 Epidemiology
2.3 Disease Burden
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.7 Pathophysiology
2.8 Treatment and Management Pattern
2.9 GlobalData Pipeline Report Guidance
3 HEPATITIS B THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Hepatitis B Therapeutics Market Size (2006 - 2011) - Global
3.2 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Global
3.3 Hepatitis B Therapeutics Market Size (2006 - 2011) - The US
3.4 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The US
3.5 Hepatitis B Therapeutics Market Size (2006 - 2011) - France
3.6 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - France
3.7 Hepatitis B Therapeutics Market Size (2006 - 2011) - Germany
3.8 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Germany
3.9 Hepatitis B Therapeutics Market Size (2006 - 2011) - Italy
3.10 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Italy
3.11 Hepatitis B Therapeutics Market Size (2006 - 2011) - Spain
3.12 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Spain
3.13 Hepatitis B Therapeutics Market Size (2006 - 2011) - The UK
3.14 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The UK
3.15 Hepatitis B Therapeutics Market Size (2006 - 2011) - Japan
3.16 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Japan
3.17 Drivers and Barriers for the Hepatitis B Therapeutics Market
3.17.1 Drivers for the Hepatitis B Therapeutics Market
3.17.2 Barriers for the Hepatitis B Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 HEPATITIS B THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Drugs
4.3.1 Intron A (interferon alpha 2b)
4.3.2 Pegasys (peginterferon alfa-2a)
4.3.3 Baraclude (entecavir)
4.3.4 Tyzeka (telbivudine)
4.3.5 Hepsera (adevofir)
4.3.6 Epivir-HBV (lamivudine)
4.3.7 Viread (tenovofir)
4.4 Key Takeaway
5 HEPATITIS B THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Hepatitis B Therapeutics - Pipeline Analysis by Clinical Phase of Development
5.3.1 Hepatitis B Therapeutics - Phase III Clinical Pipeline
5.3.2 Hepatitis B Therapeutics - Phase II Clinical Pipeline
5.3.3 Hepatitis B Therapeutics - Phase I Pipeline
5.3.4 Hepatitis B Therapeutics - Preclinical Phase Pipeline
5.3.5 Hepatitis B Therapeutics - NA Phase Pipeline
5.4 Hepatitis B Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Key Takeaway
6 HEPATITIS B THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Overview
6.2 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.3 Clinical Trials by Phase of Clinical Development
6.4 Clinical Trials by Trial Status
6.5 Prominent Sponsors
6.6 Clinical Trials by Sponsors
6.7 Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
6.8 Key Takeaway
7 HEPATITIS B THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 HEPATITIS B THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Bristol-Myers Squibb Company
8.2.2 Gilead Sciences
8.2.3 GlaxoSmithKline Plc
8.2.4 F. Hoffmann-La Roche
8.2.5 Merck & Co. Inc.
8.2.6 Novartis AG
8.3 Other Companies
8.4 Key Takeaway
9 HEPATITIS B THERAPEUTICS - LICENSING & PARTNERSHIP DEALS
10 HEPATITIS B THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Hepatitis B - Nomenclature of Hepatitis B
Table 2: Hepatitis B - Laboratory Nomenclature
Table 3: Hepatitis B - Approved Vaccines for Hepatitis B
Table 4: Hepatitis B - Approved Drugs for Hepatitis B
Table 5: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Table 6: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Table 7: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Table 8: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019
Table 9: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011
Table 10: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019
Table 11: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Table 12: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Table 13: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Table 14: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Table 15: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Table 16: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Table 17: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011
Table 18: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019
Table 19: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Table 20: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Table 21: Histological Improvement and Change in Ishak Fibrosis Score at Week 52 (007 GLOBE Study)
Table 22: The Results for Measures of Response Included Change in Serum HBV DNA, Change in ALT, HBeAg loss and HBeAg Seroconversion (437 Only)
Table 23: Changes in Ishak Fibrosis Score at Week 48
Table 24: Histologic Response at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo
Table 25: HBeAg Seroconversion at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo
Table 26: Clinical Study Results - Viread
Table 27: Hepatitis B Therapeutics Market, Phase III Pipeline, 2011
Table 28: Hepatitis B Therapeutics Market, Phase II Pipeline, 2011
Table 29: Hepatitis B Therapeutics Market, Phase I Pipeline, 2011
Table 30: Hepatitis B Therapeutics Market, Preclinical Phase Pipeline, 2011
Table 31: Hepatitis B Therapeutics Market, NA Phase Pipeline, 2011
Table 32: Hepatitis B Therapeutics, Global, Clinical Trials, 2011
Table 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2011
Table 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 35: Hepatitis B Therapeutics, Global, Prominent Sponsors, 2011
Table 36: Hepatitis B Therapeutics, Global, Overall Sponsors, 2011
Table 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011
Table 38: Bristol-Myers Squibb Company - Pipeline, 2011
Table 39: Gilead Sciences - Pipeline, 2011
Table 40: GlaxoSmithKline Plc. - Pipeline, 2011
Table 41: Other Companies - Hepatitis B Therapeutics, 2011
Table 42: Hepatitis B Therapeutics, Global, Deals - 2011
LIST OF FIGURES
Figure 1: Genotype of Hepatitis B Virus and its Geographical Distribution
Figure 2: Hepatitis B - Prevalence of HBV Infection in the World by Country
Figure 3: Hepatitis B - Areas and Features of Hepatitis B Prevalence
Figure 4: Geographic Patterns of Hepatitis B Disease Burden
Figure 5: Structure of Hepatitis B Virus
Figure 6: Summary of Hepatitis B Virus Characteristics
Figure 7: Hepatitis B - Interpretation of Hepatitis B Virus Serology
Figure 8: Hepatitis B - Life Cycle of HBV
Figure 9: Hepatitis B - Spectrum of Liver Disease After HBV Infection
Figure 10: Hepatitis B - Childhood Vaccination Schedule
Figure 11: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Figure 12: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Figure 13: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Figure 14: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019
Figure 15: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011
Figure 16: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019
Figure 17: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Figure 18: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Figure 19: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Figure 20: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Figure 21: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Figure 22: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Figure 23: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011
Figure 24: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019
Figure 25: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Figure 26: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Figure 27: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market
Figure 28: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Therapeutics, 2011
Figure 29: Hepatitis B Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 30: Hepatitis B Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011
Figure 31: Technology Trends Analytics Framework, 2011
Figure 32: Hepatitis B Therapeutics, Global, Clinical Trials by Country, 2011
Figure 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2011
Figure 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development (%), 2011
Figure 35: Hepatitis B Therapeutics, Global, Prominent Sponsors (%), 2011
Figure 36: Hepatitis B Therapeutics, Global, Overall Sponsors (%), 2011
Figure 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011
Figure 38: Hepatitis B Therapeutics Market, Drivers and Restraints, 2011
Figure 39: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2011
Figure 40: Hepatitis B Therapeutics Market, Clinical Pipeline by Company, 2011
Figure 41: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Bristol-Myers Squibb Company
Gilead Sciences
GlaxoSmithKline Plc
F. Hoffmann-La Roche
Merck & Co. Inc.
Novartis AG
1.1 List of Tables
1.2 List of Figures
2 HEPATITIS B THERAPEUTICS - INTRODUCTION
2.1 Overview
2.2 Epidemiology
2.3 Disease Burden
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.7 Pathophysiology
2.8 Treatment and Management Pattern
2.9 GlobalData Pipeline Report Guidance
3 HEPATITIS B THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Hepatitis B Therapeutics Market Size (2006 - 2011) - Global
3.2 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Global
3.3 Hepatitis B Therapeutics Market Size (2006 - 2011) - The US
3.4 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The US
3.5 Hepatitis B Therapeutics Market Size (2006 - 2011) - France
3.6 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - France
3.7 Hepatitis B Therapeutics Market Size (2006 - 2011) - Germany
3.8 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Germany
3.9 Hepatitis B Therapeutics Market Size (2006 - 2011) - Italy
3.10 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Italy
3.11 Hepatitis B Therapeutics Market Size (2006 - 2011) - Spain
3.12 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Spain
3.13 Hepatitis B Therapeutics Market Size (2006 - 2011) - The UK
3.14 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The UK
3.15 Hepatitis B Therapeutics Market Size (2006 - 2011) - Japan
3.16 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Japan
3.17 Drivers and Barriers for the Hepatitis B Therapeutics Market
3.17.1 Drivers for the Hepatitis B Therapeutics Market
3.17.2 Barriers for the Hepatitis B Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 HEPATITIS B THERAPEUTICS - COMPETITIVE ASSESSMENT
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Drugs
4.3.1 Intron A (interferon alpha 2b)
4.3.2 Pegasys (peginterferon alfa-2a)
4.3.3 Baraclude (entecavir)
4.3.4 Tyzeka (telbivudine)
4.3.5 Hepsera (adevofir)
4.3.6 Epivir-HBV (lamivudine)
4.3.7 Viread (tenovofir)
4.4 Key Takeaway
5 HEPATITIS B THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Hepatitis B Therapeutics - Pipeline Analysis by Clinical Phase of Development
5.3.1 Hepatitis B Therapeutics - Phase III Clinical Pipeline
5.3.2 Hepatitis B Therapeutics - Phase II Clinical Pipeline
5.3.3 Hepatitis B Therapeutics - Phase I Pipeline
5.3.4 Hepatitis B Therapeutics - Preclinical Phase Pipeline
5.3.5 Hepatitis B Therapeutics - NA Phase Pipeline
5.4 Hepatitis B Therapeutics - Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Key Takeaway
6 HEPATITIS B THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Overview
6.2 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.3 Clinical Trials by Phase of Clinical Development
6.4 Clinical Trials by Trial Status
6.5 Prominent Sponsors
6.6 Clinical Trials by Sponsors
6.7 Top Companies Participating in Hepatitis B Therapeutics Clinical Trials
6.8 Key Takeaway
7 HEPATITIS B THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 HEPATITIS B THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Bristol-Myers Squibb Company
8.2.2 Gilead Sciences
8.2.3 GlaxoSmithKline Plc
8.2.4 F. Hoffmann-La Roche
8.2.5 Merck & Co. Inc.
8.2.6 Novartis AG
8.3 Other Companies
8.4 Key Takeaway
9 HEPATITIS B THERAPEUTICS - LICENSING & PARTNERSHIP DEALS
10 HEPATITIS B THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Hepatitis B - Nomenclature of Hepatitis B
Table 2: Hepatitis B - Laboratory Nomenclature
Table 3: Hepatitis B - Approved Vaccines for Hepatitis B
Table 4: Hepatitis B - Approved Drugs for Hepatitis B
Table 5: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Table 6: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Table 7: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Table 8: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019
Table 9: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011
Table 10: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019
Table 11: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Table 12: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Table 13: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Table 14: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Table 15: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Table 16: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Table 17: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011
Table 18: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019
Table 19: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Table 20: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Table 21: Histological Improvement and Change in Ishak Fibrosis Score at Week 52 (007 GLOBE Study)
Table 22: The Results for Measures of Response Included Change in Serum HBV DNA, Change in ALT, HBeAg loss and HBeAg Seroconversion (437 Only)
Table 23: Changes in Ishak Fibrosis Score at Week 48
Table 24: Histologic Response at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo
Table 25: HBeAg Seroconversion at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo
Table 26: Clinical Study Results - Viread
Table 27: Hepatitis B Therapeutics Market, Phase III Pipeline, 2011
Table 28: Hepatitis B Therapeutics Market, Phase II Pipeline, 2011
Table 29: Hepatitis B Therapeutics Market, Phase I Pipeline, 2011
Table 30: Hepatitis B Therapeutics Market, Preclinical Phase Pipeline, 2011
Table 31: Hepatitis B Therapeutics Market, NA Phase Pipeline, 2011
Table 32: Hepatitis B Therapeutics, Global, Clinical Trials, 2011
Table 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2011
Table 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 35: Hepatitis B Therapeutics, Global, Prominent Sponsors, 2011
Table 36: Hepatitis B Therapeutics, Global, Overall Sponsors, 2011
Table 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011
Table 38: Bristol-Myers Squibb Company - Pipeline, 2011
Table 39: Gilead Sciences - Pipeline, 2011
Table 40: GlaxoSmithKline Plc. - Pipeline, 2011
Table 41: Other Companies - Hepatitis B Therapeutics, 2011
Table 42: Hepatitis B Therapeutics, Global, Deals - 2011
LIST OF FIGURES
Figure 1: Genotype of Hepatitis B Virus and its Geographical Distribution
Figure 2: Hepatitis B - Prevalence of HBV Infection in the World by Country
Figure 3: Hepatitis B - Areas and Features of Hepatitis B Prevalence
Figure 4: Geographic Patterns of Hepatitis B Disease Burden
Figure 5: Structure of Hepatitis B Virus
Figure 6: Summary of Hepatitis B Virus Characteristics
Figure 7: Hepatitis B - Interpretation of Hepatitis B Virus Serology
Figure 8: Hepatitis B - Life Cycle of HBV
Figure 9: Hepatitis B - Spectrum of Liver Disease After HBV Infection
Figure 10: Hepatitis B - Childhood Vaccination Schedule
Figure 11: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011
Figure 12: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019
Figure 13: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Figure 14: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019
Figure 15: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011
Figure 16: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019
Figure 17: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Figure 18: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019
Figure 19: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Figure 20: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019
Figure 21: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Figure 22: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019
Figure 23: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011
Figure 24: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019
Figure 25: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Figure 26: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019
Figure 27: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market
Figure 28: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Therapeutics, 2011
Figure 29: Hepatitis B Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 30: Hepatitis B Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011
Figure 31: Technology Trends Analytics Framework, 2011
Figure 32: Hepatitis B Therapeutics, Global, Clinical Trials by Country, 2011
Figure 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2011
Figure 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development (%), 2011
Figure 35: Hepatitis B Therapeutics, Global, Prominent Sponsors (%), 2011
Figure 36: Hepatitis B Therapeutics, Global, Overall Sponsors (%), 2011
Figure 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011
Figure 38: Hepatitis B Therapeutics Market, Drivers and Restraints, 2011
Figure 39: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2011
Figure 40: Hepatitis B Therapeutics Market, Clinical Pipeline by Company, 2011
Figure 41: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Bristol-Myers Squibb Company
Gilead Sciences
GlaxoSmithKline Plc
F. Hoffmann-La Roche
Merck & Co. Inc.
Novartis AG
